Diagnosis and Treatment of Blood Diseases
A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Clinical Medicine, Cell, and Organism Physiology".
Deadline for manuscript submissions: closed (20 September 2023) | Viewed by 196
Special Issue Editor
Special Issue Information
Dear Colleagues,
Hematological diseases derive from several lineages of cells, including myeloid cells, lymphocytes, erythrocytes and megakaryocytes. So, there are a range of different diseases classified as blood diseases, with different underlying mechanisms. Recently, as new technologies and new drugs were widely used in clinical practice, a new understanding of the blood diseases was developed. In this Special Issue, we will introduce new clinical findings and new therapies in blood diseases, especially in lymphoma, myeloma, leukemia, myeloproliferative neoplasms, bone marrow failure syndrome and hemophagocytic lymphohistiocytosis.
I have studied the immune abnormalities of immune thrombocytopenia for years. My colleagues and I have demonstrated changes of different kinds immune cells, including Tregs and Th17 cells, B10 cells, and macrophages. We are also interested in the new breakthrough in immunology and whether these developments could bring a new discovery in ITP. In this Special Issue, we will also introduce new progress in the immune mechanism of ITP.
In the era of COVID-19, most hematological patients are immunocompromised hosts. The current knowledge, such as the outcome of viral infection in China, will also be reported in this Special Issue.
We also welcome other new knowledge regarding new diagnosis and treatment of blood diseases.
Dr. Lili Ji
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- thrombocytopenia
- immune metabolism
- mitochondria
- leukemia
- myeloma
- lymphoma
- myeloproliferative neoplasms
- COVID-19
- aplastic anemia
- hemophagocytic lymphohistiocytosis
